Your browser doesn't support javascript.
loading
Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up: analyses stratified by gender from a large prospective cohort.
Ghosn, Jade; Bachelet, Delphine; Livrozet, Marine; Cervantes-Gonzalez, Minerva; Poissy, Julien; Goehringer, François; Gandonniere, Charlotte Salmon; Maillet, Mylène; Bani-Sadr, Firouzé; Martin-Blondel, Guillaume; Tattevin, Pierre; Launay, Odile; Surgers, Laure; Dudoignon, Emmanuel; Liegeon, Geoffroy; Zucman, David; Joseph, Cédric; Senneville, Eric; Yelnik, Cécile; Roger, Pierre-Marie; Faure, Karine; Gousseff, Marie; Cabié, André; Duval, Xavier; Chirouze, Catherine; Laouénan, Cédric.
Afiliación
  • Ghosn J; Université Paris Cité, INSERM, IAME UMR 1137, Paris, France; AP-HP.Nord, Service des maladies infectieuses et tropicales, Hôpital Bichat, Paris, France.
  • Bachelet D; INSERM, Centre d'Investigation clinique 1425, Hôpital Bichat, Paris, France; AP-HP.Nord, Département d'Epidémiologie Biostatistique et Recherche Clinique, Hôpital Bichat, Paris, France.
  • Livrozet M; Université Paris Cité, INSERM, PARCC, CIC1418; DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.
  • Cervantes-Gonzalez M; Université Paris Cité, INSERM, IAME UMR 1137, Paris, France; AP-HP.Nord, Service des maladies infectieuses et tropicales, Hôpital Bichat, Paris, France; AP-HP.Nord, Département d'Epidémiologie Biostatistique et Recherche Clinique, Hôpital Bichat, Paris, France.
  • Poissy J; Université de Lille, INSERM U128, CHU Lille, Pôle de réanimation, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, Lille, France.
  • Goehringer F; Service des maladies infectieuses, CHRU-Nancy, Université de Lorraine, Nancy, France.
  • Gandonniere CS; Médecine Intensive Réanimation, INSERM CIC 1415, CRICS-TriGGERSep network, CHRU de Tours, Tours, France.
  • Maillet M; Service de Maladies Infectieuses - Médecine Interne, Centre Hospitalier Annecy Genevois, Epagny Metz Tessy, France.
  • Bani-Sadr F; CHU Reims, Service des Maladies Infectieuses et Tropicales, Reims, France.
  • Martin-Blondel G; Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, & Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France.
  • Tattevin P; Hôpital Pontchaillou, Maladies Infectieuses et Réanimation, CHU Rennes, France.
  • Launay O; Université Paris Cité, CIC Cochin-Pasteur, AP-HP, Hôpital Cochin, INSERM CIC1417, Paris, France.
  • Surgers L; GHU APHP.Sorbonne Université, Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
  • Dudoignon E; AP-HP.Nord, Hôpital Saint-Louis, Service d'anesthésie-réanimation-CTB, DMU PARABOL, Université Paris Cité, Paris, France.
  • Liegeon G; AP-HP.Nord, Hôpital Saint-Louis, Service des Maladies Infectieuses et Tropicales, Université Paris Cité, Paris, France.
  • Zucman D; Service de Médecine Interne, Hôpital Foch, Suresnes, France.
  • Joseph C; CHU Amiens-Picardie, Service des Maladies Infectieuses et Tropicales; EA 4294, AGIR, Jules Verne Picardy University, Amiens, France.
  • Senneville E; Service des Maladies Infectieuses, Hôpital de Tourcoing, France.
  • Yelnik C; Département de Médecine Interne et Immunologie Clinique, CHU Lille, France.
  • Roger PM; Centre Hospitalier Universitaire de Guadeloupe, UMR 1058 Pathogenesis and Control of Chronic and Emerging Infections, Guadeloupe, France.
  • Faure K; Service de Maladies Infectieuses, CHU, Lille, France.
  • Gousseff M; Service de Médecine Interne, Maladies Infectieuses et Hématologie, Centre Hospitalier Bretagne Atlantique, Vannes, France.
  • Cabié A; CHU de Martinique, Fort-de-France; PCCEI, Univ Montpellier, Univ Antilles, INSERM, EFS, Montpellier; and INSERM CIC1424, Fort-de-France, France.
  • Duval X; Université Paris Cité, INSERM, IAME UMR 1137, Paris, France; INSERM, Centre d'Investigation clinique 1425, Hôpital Bichat, Paris, France.
  • Chirouze C; Chrono-environnement UMR6249, CNRS, Université Bourgogne Franche-Comté; CHU Besançon, service de maladies infectieuses et tropicales, Besançon, France.
  • Laouénan C; Université Paris Cité, INSERM, IAME UMR 1137, Paris, France; INSERM, Centre d'Investigation clinique 1425, Hôpital Bichat, Paris, France; AP-HP.Nord, Département d'Epidémiologie Biostatistique et Recherche Clinique, Hôpital Bichat, Paris, France. Electronic address: cedric.laouenan@inserm.fr.
Clin Microbiol Infect ; 29(2): 254.e7-254.e13, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36191847
OBJECTIVES: Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort. METHODS: Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender. RESULTS: We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale <57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%). CONCLUSIONS: One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude / Patient_preference Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Microbiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude / Patient_preference Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Microbiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido